Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diag...

Full description

Saved in:
Bibliographic Details
Published inPLoS medicine Vol. 10; no. 9; p. e1001510
Main Authors Mocroft, Amanda, Lundgren, Jens D., Sabin, Miriam Lewis, Monforte, Antonella d'Arminio, Brockmeyer, Norbert, Casabona, Jordi, Castagna, Antonella, Costagliola, Dominique, Dabis, Francois, De Wit, Stéphane, Fätkenheuer, Gerd, Furrer, Hansjakob, Johnson, Anne M., Lazanas, Marios K., Leport, Catherine, Moreno, Santiago, Obel, Niels, Post, Frank A., Reekie, Joanne, Reiss, Peter, Sabin, Caroline, Skaletz-Rorowski, Adriane, Suarez-Lozano, Ignacio, Torti, Carlo, Warszawski, Josiane, Zangerle, Robert, Fabre-Colin, Céline, Kjaer, Jesper, Chene, Genevieve, Grarup, Jesper, Kirk, Ole
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 01.09.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text
ISSN1549-1676
1549-1277
1549-1676
DOI10.1371/journal.pmed.1001510

Cover

Loading…
Abstract Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP.
AbstractList Please see later in the article for the Editors' Summary.
Background: Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. Methods and Findings: LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/[mm.sup.3] or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries(57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96;95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users(IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19- 20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). Conclusions:LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. Please see later in the article for the Editors' Summary.
BackgroundFew studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.Methods and findingsLP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43).ConclusionsLP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP.
  Background Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. Methods and Findings LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm3 or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). Conclusions LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. Please see later in the article for the Editors' Summary
Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP.
Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.BACKGROUNDFew studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality.LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43).METHODS AND FINDINGSLP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm(3) or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43).LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP.CONCLUSIONSLP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP.
Amanda Mocroft and colleagues investigate risk factors and health outcomes associated with diagnosis at a late stage of infection in individuals across Europe. Please see later in the article for the Editors' Summary
Amanda Mocroft and colleagues investigate risk factors and health outcomes associated with diagnosis at a late stage of infection in individuals across Europe. Please see later in the article for the Editors' Summary Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality. LP was defined in Collaboration of Observational HIV Epidemiological Research Europe (COHERE) as HIV diagnosis with a CD4 count <350/mm3 or an AIDS diagnosis within 6 months of HIV diagnosis among persons presenting for care between 1 January 2000 and 30 June 2011. Logistic regression was used to identify factors associated with LP and Poisson regression to explore the impact on AIDS/death. 84,524 individuals from 23 cohorts in 35 countries contributed data; 45,488 were LP (53.8%). LP was highest in heterosexual males (66.1%), Southern European countries (57.0%), and persons originating from Africa (65.1%). LP decreased from 57.3% in 2000 to 51.7% in 2010/2011 (adjusted odds ratio [aOR] 0.96; 95% CI 0.95-0.97). LP decreased over time in both Central and Northern Europe among homosexual men, and male and female heterosexuals, but increased over time for female heterosexuals and male intravenous drug users (IDUs) from Southern Europe and in male and female IDUs from Eastern Europe. 8,187 AIDS/deaths occurred during 327,003 person-years of follow-up. In the first year after HIV diagnosis, LP was associated with over a 13-fold increased incidence of AIDS/death in Southern Europe (adjusted incidence rate ratio [aIRR] 13.02; 95% CI 8.19-20.70) and over a 6-fold increased rate in Eastern Europe (aIRR 6.64; 95% CI 3.55-12.43). LP has decreased over time across Europe, but remains a significant issue in the region in all HIV exposure groups. LP increased in male IDUs and female heterosexuals from Southern Europe and IDUs in Eastern Europe. LP was associated with an increased rate of AIDS/deaths, particularly in the first year after HIV diagnosis, with significant variation across Europe. Earlier and more widespread testing, timely referrals after testing positive, and improved retention in care strategies are required to further reduce the incidence of LP. Please see later in the article for the Editors' Summary Every year about 2.5 million people become newly infected with HIV, the virus that causes AIDS. HIV can be transmitted through unprotected sex with an infected partner, from an HIV-positive mother to her unborn baby, or through injection of drugs. Most people do not become ill immediately after infection with HIV although some develop a short influenza-like illness. The next stage of the HIV infection, which may last up to 10 years, also has no major symptoms but, during this stage, HIV slowly destroys immune system cells, including CD4 cells, a type of lymphocyte. Eventually, when the immune system is unable to fight off infections by other disease-causing organisms, HIV-positive people develop AIDS-defining conditions-unusual viral, bacterial, and fungal infections and unusual tumors. Progression to AIDS occurs when any severe AIDS-defining condition is diagnosed, when the CD4 count in the blood falls below 200 cells/mm3, or when CD4 cells account for fewer than 15% of lymphocytes. People need to know they are HIV positive as soon as possible after they become infected because antiretroviral therapy, which controls but does not cure HIV infection, works best if it is initiated when people still have a relatively high CD4 count. Early diagnosis also reduces the risk of onward HIV transmission. However, 40%-60% of HIV-positive individuals in developed countries are not diagnosed until they have a low CD4 count or an AIDS-defining illness. Reasons for such late presentation include fear of discrimination or stigmatization, limited knowledge about HIV risk factors, testing, and treatment together with missed opportunities to offer an HIV test. Policy makers involved in national and international HIV control programs need detailed information about patterns of late presentation before they can make informed decisions about how to reduce this problem. In this study, therefore, the researchers use data collected by the Collaboration of Observational HIV Epidemiological Research in Europe (COHERE) to analyze trends in late presentation over time across Europe and in different groups of people at risk of HIV infection and to investigate the clinical consequences of late presentation. The researchers analyzed data collected from 84,524 individuals participating in more than 20 observational studies that were undertaken in 35 European countries and that investigated outcomes among HIV-positive people. Nearly 54% of the participants were late presenters-individuals who had a CD4 count of less than 350 cells/mm3 or an AIDS-defining illness within 6 months of HIV diagnosis. Late presentation was highest among heterosexual males, in Southern European countries, and among people originating in Africa. Overall, late presentation decreased from 57.3% in 2000 to 51.7% in 2010/11. However, whereas late presentation decreased over time among men having sex with men in Central and Northern Europe, for example, it increased over time among female heterosexuals in Southern Europe. Finally, among the 8,000 individuals who developed a new AIDS-defining illness or died during follow-up, compared to non-late presentation, late presentation was associated with an increased incidence of AIDS/death in all regions of Europe during the first and second year after HIV diagnosis (but not in later years); the largest increase in incidence (13-fold) occurred during the first year after diagnosis in Southern Europe. These findings indicate that, although late presentation with HIV infection has decreased in recent years, it remains an important issue across Europe and in all...
Audience Academic
Author Reekie, Joanne
Brockmeyer, Norbert
Casabona, Jordi
Torti, Carlo
Reiss, Peter
Skaletz-Rorowski, Adriane
Johnson, Anne M.
De Wit, Stéphane
Castagna, Antonella
Sabin, Miriam Lewis
Fabre-Colin, Céline
Leport, Catherine
Lundgren, Jens D.
Costagliola, Dominique
Chene, Genevieve
Sabin, Caroline
Kjaer, Jesper
Suarez-Lozano, Ignacio
Mocroft, Amanda
Furrer, Hansjakob
Lazanas, Marios K.
Fätkenheuer, Gerd
Dabis, Francois
Moreno, Santiago
Monforte, Antonella d'Arminio
Post, Frank A.
Zangerle, Robert
Warszawski, Josiane
Obel, Niels
Grarup, Jesper
Kirk, Ole
AuthorAffiliation 19 Kings College London School of Medicine, London, United Kingdom
1 Department of Infection and Population Health, University College London, London, United Kingdom
5 Department of Dermatology, Venerology, and Allergology, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany
23 German Competence Network for HIV/AIDS, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany
29 Université de Bordeaux, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France
25 University Division of Infectious and Tropical Diseases, University and Spedali Civili of Brescia, Brescia, Italy
10 Université of Bordeaux, ISPED, Centre Inserm, U897–Epidémiologie–Biostatistiques, Bordeaux, France
13 Universität Köln, Cologne, Germany
15 3rd Internal Medicine Department and Infectious Disease Unit, Red Cross General Hospital of Athens, Greece
30 INSERM, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France
Centers for Disease Control and Prevention, United States of America
16 Unive
AuthorAffiliation_xml – name: 2 Copenhagen HIV programme, University of Copenhagen, Copenhagen, Denmark
– name: 26 Department of Medical and Surgical Sciences, Unit of Infectious Diseases, University “Magna Graecia,” Catanzaro, Italy
– name: 5 Department of Dermatology, Venerology, and Allergology, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany
– name: 11 Inserm U897–Epidémiologie–Biostatistiques, Bordeaux, France
– name: 13 Universität Köln, Cologne, Germany
– name: 10 Université of Bordeaux, ISPED, Centre Inserm, U897–Epidémiologie–Biostatistiques, Bordeaux, France
– name: 16 Université Paris Diderot, Sorbonne Paris Cité, UMR 738, Paris, France
– name: Centers for Disease Control and Prevention, United States of America
– name: 15 3rd Internal Medicine Department and Infectious Disease Unit, Red Cross General Hospital of Athens, Greece
– name: 8 UPMC Université Paris 06, UMR_S 943, Paris, France
– name: 20 The Kirby Institute, University of New South Wales, Sydney, Australia
– name: 6 CEEISCAT (Agència de Salut Pública de Catalunya) and CIBERESP, Badalona, Catalonia, Spain
– name: 19 Kings College London School of Medicine, London, United Kingdom
– name: 14 Department of Infectious Diseases, Bern University Hospital and University of Bern, Bern, Switzerland
– name: 22 Stichting HIV Monitoring, Amsterdam, The Netherlands
– name: 21 Academisch Medisch Centrum bij de Universiteit van Amsterdam, Amsterdam, The Netherlands
– name: 27 INSERM CESP U1018, Université Paris-Sud, AP-HP Public Health Department, Le Kremlin-Bicêtre, France
– name: 29 Université de Bordeaux, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France
– name: 28 Medical University Innsbruck, Innsbruck, Austria
– name: 3 Department of Infectious Diseases, Copenhagen University Hospital/Rigshospitalet, Copenhagen, Denmark
– name: 25 University Division of Infectious and Tropical Diseases, University and Spedali Civili of Brescia, Brescia, Italy
– name: 7 Department of Infectious Diseases IRCCS San Raffaele, Milan, Italy
– name: 30 INSERM, ISPED, Centre INSERM U897-Epidémiologie Statistique, Bordeaux, France
– name: 1 Department of Infection and Population Health, University College London, London, United Kingdom
– name: 23 German Competence Network for HIV/AIDS, St. Josef Hospital, Ruhr-Universität Bochum, Bochum, Germany
– name: 18 Department of Infectious Diseases. University Hospital Ramón y Cajal, IRYCIS, Madrid, Spain
– name: 24 Infectious Diseases Unit, Complejo Hospitalario de Huelva, Spanish VACH Cohort, Spain
– name: 12 Saint-Pierre Hospital, Brussels, Belgium
– name: 4 Department of Health Sciences, Institute of Infectious Diseases, Milan, Italy
– name: 17 INSERM, UMR 738, Paris, France
– name: 9 INSERM, UMR_S 943, Paris, France
Author_xml – sequence: 1
  givenname: Amanda
  surname: Mocroft
  fullname: Mocroft, Amanda
– sequence: 2
  givenname: Jens D.
  surname: Lundgren
  fullname: Lundgren, Jens D.
– sequence: 3
  givenname: Miriam Lewis
  surname: Sabin
  fullname: Sabin, Miriam Lewis
– sequence: 4
  givenname: Antonella d'Arminio
  surname: Monforte
  fullname: Monforte, Antonella d'Arminio
– sequence: 5
  givenname: Norbert
  surname: Brockmeyer
  fullname: Brockmeyer, Norbert
– sequence: 6
  givenname: Jordi
  surname: Casabona
  fullname: Casabona, Jordi
– sequence: 7
  givenname: Antonella
  surname: Castagna
  fullname: Castagna, Antonella
– sequence: 8
  givenname: Dominique
  surname: Costagliola
  fullname: Costagliola, Dominique
– sequence: 9
  givenname: Francois
  surname: Dabis
  fullname: Dabis, Francois
– sequence: 10
  givenname: Stéphane
  surname: De Wit
  fullname: De Wit, Stéphane
– sequence: 11
  givenname: Gerd
  surname: Fätkenheuer
  fullname: Fätkenheuer, Gerd
– sequence: 12
  givenname: Hansjakob
  surname: Furrer
  fullname: Furrer, Hansjakob
– sequence: 13
  givenname: Anne M.
  surname: Johnson
  fullname: Johnson, Anne M.
– sequence: 14
  givenname: Marios K.
  surname: Lazanas
  fullname: Lazanas, Marios K.
– sequence: 15
  givenname: Catherine
  surname: Leport
  fullname: Leport, Catherine
– sequence: 16
  givenname: Santiago
  surname: Moreno
  fullname: Moreno, Santiago
– sequence: 17
  givenname: Niels
  surname: Obel
  fullname: Obel, Niels
– sequence: 18
  givenname: Frank A.
  surname: Post
  fullname: Post, Frank A.
– sequence: 19
  givenname: Joanne
  surname: Reekie
  fullname: Reekie, Joanne
– sequence: 20
  givenname: Peter
  surname: Reiss
  fullname: Reiss, Peter
– sequence: 21
  givenname: Caroline
  surname: Sabin
  fullname: Sabin, Caroline
– sequence: 22
  givenname: Adriane
  surname: Skaletz-Rorowski
  fullname: Skaletz-Rorowski, Adriane
– sequence: 23
  givenname: Ignacio
  surname: Suarez-Lozano
  fullname: Suarez-Lozano, Ignacio
– sequence: 24
  givenname: Carlo
  surname: Torti
  fullname: Torti, Carlo
– sequence: 25
  givenname: Josiane
  surname: Warszawski
  fullname: Warszawski, Josiane
– sequence: 26
  givenname: Robert
  surname: Zangerle
  fullname: Zangerle, Robert
– sequence: 27
  givenname: Céline
  surname: Fabre-Colin
  fullname: Fabre-Colin, Céline
– sequence: 28
  givenname: Jesper
  surname: Kjaer
  fullname: Kjaer, Jesper
– sequence: 29
  givenname: Genevieve
  surname: Chene
  fullname: Chene, Genevieve
– sequence: 30
  givenname: Jesper
  surname: Grarup
  fullname: Grarup, Jesper
– sequence: 31
  givenname: Ole
  surname: Kirk
  fullname: Kirk, Ole
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24137103$$D View this record in MEDLINE/PubMed
BookMark eNqVk91q2zAUgM3oWH-2NxiboDDai2SSJdlWLwYlpGugLCXdeitk-ThR51iZJJf1xfZ8k5t0NKOMDl_YPv7OJ_nonP1kp7UtJMlbgoeE5uTjje1cq5rhagnVkGBMOMEvkj3CmRiQLM92Hj3vJvve32CcCizwq2Q3Zb0C073k18z47-hM6WCdR6qt0LQL2i7Bo9o6dKECoEsHHtqggrHtffR8cj24tN4Ecxu_gvO29ci0aNw5u4ITNAPfNSEanF2isAA0sk2jSuvWClujaenB3d6_qqb3ofHKVLA0trFzo2MsOkA5vdhI0VXoqjt0NJqej2fj49fJy1o1Ht5s7gfJt7Px19H54GL6eTI6vRjoXPAwIJBWGTDNoNREp4qnLK1YoYCDEIQVtBZE8KJUBeelpmkNWV1ShTVTRZlWgh4k79feVWO93JTcS8JYSgXmRRaJyZqorLqRK2eWyt1Jq4y8D1g3l8oFoxuQBMosLwCnqsCMqVwoQuuMFwUmmdIlia5Pm9W6Mp6qjkV3qtmSbn9pzULO7a2kucgEy6PgaCNw9kcHPsil8Rpi8VuwXb9vXnBKMU2fgTIqRBSziB6u0bmKf2Ha2sbFdY_LU8pynqZc4EgNnqDm0ELcaWzd2sTwFj98go9X3wb6yYTjrYTIBPgZ5qrzXk6uZv_Bfnk-O73eZj88YhegmrDwtun6Rvbb4LvHR_nnDB8mLwIna0A7672DWmqzHrFYBtNIgmVPPvSc7MdcbsY8JrO_kh_8_0z7DSfrVl0
CitedBy_id crossref_primary_10_1097_EDE_0000000000000324
crossref_primary_10_4103_0366_6999_238152
crossref_primary_10_1590_s1980_220x2018009703439
crossref_primary_10_1097_QAI_0000000000001153
crossref_primary_10_1111_hiv_13450
crossref_primary_10_1136_bmjopen_2016_012721
crossref_primary_10_7448_IAS_17_4_19856
crossref_primary_10_1080_14787210_2018_1545575
crossref_primary_10_1093_cid_ciy103
crossref_primary_10_3390_biom9060233
crossref_primary_10_7448_IAS_17_4_19619
crossref_primary_10_1093_jac_dkw103
crossref_primary_10_1371_journal_pone_0277534
crossref_primary_10_1371_journal_pone_0249864
crossref_primary_10_1111_hiv_13323
crossref_primary_10_1371_journal_pone_0283648
crossref_primary_10_1007_s10903_017_0681_6
crossref_primary_10_1097_MD_0000000000030400
crossref_primary_10_1111_hiv_13440
crossref_primary_10_1093_jac_dkae081
crossref_primary_10_1111_hiv_12474
crossref_primary_10_2807_1560_7917_ES2015_20_14_21088
crossref_primary_10_1111_hiv_13443
crossref_primary_10_4236_wja_2014_42031
crossref_primary_10_1016_j_eclinm_2022_101600
crossref_primary_10_3390_ijerph13030320
crossref_primary_10_1186_s12879_016_1462_x
crossref_primary_10_3390_pathogens10070835
crossref_primary_10_1007_s15010_015_0745_2
crossref_primary_10_1186_s12879_017_2398_5
crossref_primary_10_2807_1560_7917_ES2015_20_14_21086
crossref_primary_10_1186_s12889_024_18499_6
crossref_primary_10_1186_s12879_017_2280_5
crossref_primary_10_1016_S2352_3018_15_00006_5
crossref_primary_10_1038_s41385_018_0083_7
crossref_primary_10_1097_CCM_0000000000001385
crossref_primary_10_1186_s12879_020_05261_7
crossref_primary_10_1186_s12879_019_4156_3
crossref_primary_10_1097_QAD_0000000000003683
crossref_primary_10_1007_s15010_016_0887_x
crossref_primary_10_1080_09540121_2018_1470306
crossref_primary_10_1111_hiv_12347
crossref_primary_10_1111_hiv_13436
crossref_primary_10_3851_IMP2990
crossref_primary_10_1080_09540121_2021_1884181
crossref_primary_10_1136_sextrans_2020_054697
crossref_primary_10_2196_resprot_5162
crossref_primary_10_58395_pipd_v50i1_80
crossref_primary_10_1093_cid_ciw065
crossref_primary_10_1097_QAI_0000000000001939
crossref_primary_10_1097_QAI_0000000000001498
crossref_primary_10_1093_eurpub_ckx225
crossref_primary_10_1080_09540121_2019_1612021
crossref_primary_10_1016_j_jinf_2016_01_017
crossref_primary_10_1186_s12889_015_2571_y
crossref_primary_10_3390_tropicalmed9090213
crossref_primary_10_1007_s11904_014_0202_3
crossref_primary_10_1371_journal_pone_0214739
crossref_primary_10_1111_1471_0528_14614
crossref_primary_10_1371_journal_pone_0176914
crossref_primary_10_5694_mja2_50006
crossref_primary_10_1097_COH_0000000000000307
crossref_primary_10_5114_amscd_2016_63157
crossref_primary_10_1097_QAI_0000000000000717
crossref_primary_10_1007_s12250_018_0028_z
crossref_primary_10_1080_09540121_2023_2185196
crossref_primary_10_1155_2023_9488051
crossref_primary_10_2807_1560_7917_ES_2024_29_48_2400759
crossref_primary_10_1007_s15010_014_0646_9
crossref_primary_10_1097_COH_0000000000000076
crossref_primary_10_1371_journal_pone_0162503
crossref_primary_10_1089_apc_2020_0044
crossref_primary_10_1093_cid_cix858
crossref_primary_10_1007_s11904_014_0198_8
crossref_primary_10_1017_S0022215119002019
crossref_primary_10_1371_journal_pone_0142576
crossref_primary_10_1016_j_antiviral_2019_104577
crossref_primary_10_1186_s12981_021_00415_2
crossref_primary_10_1186_s12889_018_5500_z
crossref_primary_10_1586_14787210_2015_1029917
crossref_primary_10_1080_09540121_2014_906554
crossref_primary_10_1097_QAD_0000000000000524
crossref_primary_10_1097_QAI_0000000000000825
crossref_primary_10_1002_jmv_28781
crossref_primary_10_1007_s15010_018_1167_8
crossref_primary_10_1093_eurpub_ckx048
crossref_primary_10_1111_hiv_13121
crossref_primary_10_1371_journal_pone_0140845
crossref_primary_10_1016_j_maturitas_2017_11_012
crossref_primary_10_1016_j_maturitas_2016_03_015
crossref_primary_10_3390_jcm10040716
crossref_primary_10_1186_s12916_017_0856_y
crossref_primary_10_1586_14787210_2016_1106937
crossref_primary_10_1016_S2352_3018_15_00252_0
crossref_primary_10_1038_s41598_021_01885_0
crossref_primary_10_1371_journal_pone_0162739
crossref_primary_10_2196_11136
crossref_primary_10_1007_s10903_016_0385_3
crossref_primary_10_1089_apc_2015_0094
crossref_primary_10_1186_s12981_016_0129_4
crossref_primary_10_1371_journal_pone_0207355
crossref_primary_10_1371_journal_pone_0143320
crossref_primary_10_7448_IAS_18_1_20024
crossref_primary_10_1097_QAD_0000000000000530
crossref_primary_10_1097_QAD_0000000000000410
crossref_primary_10_1097_QAI_0000000000001585
crossref_primary_10_1371_journal_pone_0188751
crossref_primary_10_3389_fimmu_2017_01189
crossref_primary_10_1371_journal_pone_0259073
crossref_primary_10_4103_jfmpc_jfmpc_414_21
crossref_primary_10_1186_s12879_018_3661_0
crossref_primary_10_1089_aid_2020_0175
crossref_primary_10_1007_s40121_021_00494_8
crossref_primary_10_1371_journal_pone_0118492
crossref_primary_10_1017_S0950268823000043
crossref_primary_10_1111_hiv_12735
crossref_primary_10_3389_fpubh_2023_1193236
crossref_primary_10_51523_2708_6011_2019_16_4_3
crossref_primary_10_1016_j_puhe_2016_10_009
crossref_primary_10_1111_hiv_12175
crossref_primary_10_3851_IMP2960
crossref_primary_10_1016_j_eclinm_2021_100877
crossref_primary_10_1089_apc_2016_0082
crossref_primary_10_1002_jia2_25726
crossref_primary_10_1186_s12981_019_0221_7
crossref_primary_10_1371_journal_pone_0214421
crossref_primary_10_2989_16085906_2018_1490785
crossref_primary_10_1089_aid_2014_0205
crossref_primary_10_1093_ije_dyw211
crossref_primary_10_1111_hiv_12727
crossref_primary_10_2807_1560_7917_ES_2015_20_47_30070
crossref_primary_10_1093_ve_vew010
crossref_primary_10_1007_s00103_016_2320_0
crossref_primary_10_1111_hiv_12962
crossref_primary_10_1016_j_lpm_2017_11_022
crossref_primary_10_1080_09540121_2016_1224306
crossref_primary_10_1186_1471_2334_14_S6_S18
crossref_primary_10_1093_cid_ciu1138
crossref_primary_10_1111_tmi_12746
crossref_primary_10_1310_hct1504_133
crossref_primary_10_2807_1560_7917_ES2014_19_47_20968
crossref_primary_10_1177_0956462418796445
crossref_primary_10_1089_aid_2015_0058
crossref_primary_10_2807_1560_7917_ES2013_18_48_20647
crossref_primary_10_1186_s12889_016_3477_z
crossref_primary_10_2217_fvl_15_66
crossref_primary_10_1136_sextrans_2014_051980
crossref_primary_10_1097_QAD_0000000000001411
crossref_primary_10_1371_journal_pone_0180361
crossref_primary_10_1136_bmjopen_2017_019806
crossref_primary_10_2807_1560_7917_ES_2019_24_41_1900225
crossref_primary_10_1371_journal_pone_0220108
crossref_primary_10_1007_s15010_014_0719_9
crossref_primary_10_1111_hiv_13041
crossref_primary_10_1186_s12981_015_0079_2
crossref_primary_10_2807_1560_7917_ES2014_19_47_20973
crossref_primary_10_1093_ofid_ofac611
crossref_primary_10_1186_s12879_015_0940_x
crossref_primary_10_3390_jcm8020163
crossref_primary_10_1097_MD_0000000000014664
crossref_primary_10_1155_2016_1631878
crossref_primary_10_1371_journal_pone_0284688
crossref_primary_10_2807_1560_7917_ES_2022_27_30_2100809
crossref_primary_10_1371_journal_pone_0145380
crossref_primary_10_1007_s13365_014_0266_2
crossref_primary_10_1371_journal_pone_0182335
crossref_primary_10_1080_09540121_2014_938016
crossref_primary_10_1177_0956462416649327
crossref_primary_10_1016_j_hlpt_2017_01_005
crossref_primary_10_1093_cid_ciy400
crossref_primary_10_7448_IAS_18_1_19463
crossref_primary_10_1371_journal_pone_0156360
crossref_primary_10_1097_QAI_0000000000000567
crossref_primary_10_3389_fmed_2023_1182359
crossref_primary_10_1080_09540121_2019_1576842
crossref_primary_10_1177_0956462415623402
crossref_primary_10_1097_QAD_0000000000000222
crossref_primary_10_1097_QAI_0000000000003398
crossref_primary_10_1016_j_ejim_2019_09_006
crossref_primary_10_1007_s10903_018_0834_2
crossref_primary_10_1016_j_cmi_2021_07_036
crossref_primary_10_1186_s12879_018_3251_1
crossref_primary_10_7448_IAS_18_1_20317
crossref_primary_10_1093_cid_ciy414
crossref_primary_10_1186_s12889_018_6107_0
crossref_primary_10_1111_hiv_12403
crossref_primary_10_1371_journal_pone_0218380
crossref_primary_10_1097_QAD_0000000000002891
crossref_primary_10_1111_hiv_12762
crossref_primary_10_3390_pathogens13080683
crossref_primary_10_1111_hiv_12321
crossref_primary_10_1186_s12879_018_3573_z
crossref_primary_10_1186_s12879_021_06183_8
crossref_primary_10_1371_journal_pone_0186835
crossref_primary_10_1007_s10461_018_2335_7
crossref_primary_10_1093_cid_cix212
crossref_primary_10_1097_MCG_0000000000001189
crossref_primary_10_1111_1753_6405_12910
crossref_primary_10_1093_cid_ciz877
crossref_primary_10_1186_s12879_022_07352_z
crossref_primary_10_3390_pharmacy8020092
crossref_primary_10_1002_jia2_26086
crossref_primary_10_1371_journal_pmed_1002479
crossref_primary_10_1097_QAD_0000000000000243
crossref_primary_10_1186_s13011_022_00439_5
crossref_primary_10_1111_hiv_13407
crossref_primary_10_1016_j_ijid_2018_03_007
crossref_primary_10_1016_j_ijid_2024_106995
crossref_primary_10_1097_COH_0000000000000241
crossref_primary_10_1111_hiv_12430
crossref_primary_10_1093_infdis_jiaa669
crossref_primary_10_1371_journal_pone_0113062
crossref_primary_10_1590_S1518_8787_2016050006352
crossref_primary_10_1371_journal_pone_0124741
crossref_primary_10_1186_s40249_016_0193_y
crossref_primary_10_1093_jac_dkab168
crossref_primary_10_1002_hed_25421
crossref_primary_10_1186_s12879_018_2971_6
crossref_primary_10_1111_hiv_12545
crossref_primary_10_1093_cid_cix915
crossref_primary_10_1111_hiv_12101
crossref_primary_10_1093_jac_dkv272
crossref_primary_10_2807_1560_7917_ES_2020_25_47_2001943
crossref_primary_10_1371_journal_pone_0197990
crossref_primary_10_1093_cid_civ732
crossref_primary_10_1002_jmv_28288
crossref_primary_10_1007_s15006_014_3119_2
crossref_primary_10_1097_QAD_0000000000003658
crossref_primary_10_1136_postgradmedj_2019_137093
crossref_primary_10_1038_s41598_023_50713_0
crossref_primary_10_1111_hiv_13426
crossref_primary_10_1016_S2352_3018_24_00212_1
crossref_primary_10_1097_MD_0000000000026507
crossref_primary_10_1186_s12879_018_3249_8
crossref_primary_10_1186_s12889_021_10421_8
crossref_primary_10_23950_jcmk_15488
crossref_primary_10_1371_journal_pone_0133232
crossref_primary_10_1093_cid_cix927
crossref_primary_10_1177_0956462416650980
crossref_primary_10_1136_bmjopen_2015_009688
crossref_primary_10_2196_14145
crossref_primary_10_1016_j_ijantimicag_2023_107018
crossref_primary_10_1016_j_medcli_2023_12_007
crossref_primary_10_1016_j_ijantimicag_2023_107016
crossref_primary_10_1016_j_medcle_2023_12_010
crossref_primary_10_1097_QAD_0000000000001126
crossref_primary_10_1016_j_parint_2024_102983
crossref_primary_10_1111_hiv_12686
crossref_primary_10_3389_fphar_2021_773848
Cites_doi 10.1186/1471-2458-13-281
10.1097/01.qai.0000286597.57066.2b
10.1186/1471-2334-11-11
10.1097/QAD.0b013e32801138f7
10.1001/archinte.160.17.2614
10.3109/00365548.2011.626440
10.1371/journal.pone.0041673
10.1093/eurpub/ckm117
10.3851/IMP1883
10.1097/QAD.0b013e32833f9e1d
10.3851/IMP1526
10.1016/S0140-6736(10)60232-2
10.1177/135965350701200111
10.1111/j.1468-1293.2011.00959.x
10.1097/00002030-200209270-00012
10.1097/00002030-199807000-00016
10.1097/00002030-200411050-00006
10.1177/135965350400900421
10.1056/NEJM200003303421303
10.1093/eurpub/ckp231
10.1097/MLR.0b013e3181f81c4a
10.3851/IMP1522
10.1111/j.1468-1293.2011.00958.x
10.1258/ijsa.2011.011280
10.1186/1742-6405-8-22
10.1111/j.1468-1293.2010.00857.x
10.1097/00126334-200408010-00009
10.1136/bmjopen-2012-001465
10.2807/ese.16.48.20030-en
10.1177/135965350701200612
10.1001/archinte.158.7.734
10.1371/journal.pone.0052845
ContentType Journal Article
Contributor Reekie, Joanne
Battegay, Manuel
Reiss, Peter
Skaletz-Rorowski, Adriane
Touloumi, Giota
Del Amo, Julia
Ramos, José
Costagliola, Dominique
Gibb, Diana
Sabin, Miriam
Sabin, Caroline
Thorne, Claire
Kjaer, Jesper
Krause, Murielle Mary
Mocroft, Amanda
Furrer, Hansjakob
Fätkenheuer, Gerd
Teira, Ramon
Lundgren, Jens
Dabis, Francois
de Wit, Stephane
Moreno, Santiago
Zangerle, Robert
Obel, Niels
Grarup, Jesper
Pérez-Hoyos, Santiago
Tookey, Pat
Kirk, Ole
Mussini, Cristina
de Wolf, Frank
Lazanas, Mario
Brockmeyer, Norbert
Casabona, Jordi
Torti, Carlo
Monforte, Antonella d' Arminio
Schwimmer, Christine
Ghosn, Jade
De Wit, Stéphane
Castagna, Antonella
Noguera-Julian, Antoni
Antinori, Andrea
Fabre-Colin, Céline
Leport, Catherine
Chene, Genevieve
Johnson, Hansjakob Furrer Anne
Suarez-Loano, Ignacio
Johnson, Anne
Hamouda, Osamah
Garrido, Myriam
Bucher, Heiner
Bartmeyer, Barbara
Miro, Jose M
Meyer, Laurence
Rauch, Andri
Haerry, David
Post, Frank
Goetghebuer, Tessa
Weller, Ian
Stephan, Christoph
Termote, Monique
Dabis, François
Prins, Maria
Warszawski, Josiane
Judd,
Contributor_xml – sequence: 1
  givenname: Amanda
  surname: Mocroft
  fullname: Mocroft, Amanda
– sequence: 2
  givenname: Jens
  surname: Lundgren
  fullname: Lundgren, Jens
– sequence: 3
  givenname: Miriam
  surname: Sabin
  fullname: Sabin, Miriam
– sequence: 4
  givenname: Norbert
  surname: Brockmeyer
  fullname: Brockmeyer, Norbert
– sequence: 5
  givenname: Jordi
  surname: Casabona
  fullname: Casabona, Jordi
– sequence: 6
  givenname: Antonella
  surname: Castagna
  fullname: Castagna, Antonella
– sequence: 7
  givenname: Dominique
  surname: Costagliola
  fullname: Costagliola, Dominique
– sequence: 8
  givenname: Francois
  surname: Dabis
  fullname: Dabis, Francois
– sequence: 9
  givenname: Stéphane
  surname: De Wit
  fullname: De Wit, Stéphane
– sequence: 10
  givenname: Gerd
  surname: Fätkenheuer
  fullname: Fätkenheuer, Gerd
– sequence: 11
  givenname: Hansjakob
  surname: Furrer
  fullname: Furrer, Hansjakob
– sequence: 12
  givenname: Anne
  surname: Johnson
  fullname: Johnson, Anne
– sequence: 13
  givenname: Mario
  surname: Lazanas
  fullname: Lazanas, Mario
– sequence: 14
  givenname: Catherine
  surname: Leport
  fullname: Leport, Catherine
– sequence: 15
  givenname: Santiago
  surname: Moreno
  fullname: Moreno, Santiago
– sequence: 16
  givenname: Niels
  surname: Obel
  fullname: Obel, Niels
– sequence: 17
  givenname: Frank
  surname: Post
  fullname: Post, Frank
– sequence: 18
  givenname: Joanne
  surname: Reekie
  fullname: Reekie, Joanne
– sequence: 19
  givenname: Peter
  surname: Reiss
  fullname: Reiss, Peter
– sequence: 20
  givenname: Caroline
  surname: Sabin
  fullname: Sabin, Caroline
– sequence: 21
  givenname: Adriane
  surname: Skaletz-Rorowski
  fullname: Skaletz-Rorowski, Adriane
– sequence: 22
  givenname: Ignacio
  surname: Suarez-Loano
  fullname: Suarez-Loano, Ignacio
– sequence: 23
  givenname: Josiane
  surname: Warszawski
  fullname: Warszawski, Josiane
– sequence: 24
  givenname: Robert
  surname: Zangerle
  fullname: Zangerle, Robert
– sequence: 25
  givenname: Jesper
  surname: Kjaer
  fullname: Kjaer, Jesper
– sequence: 26
  givenname: Genevieve
  surname: Chene
  fullname: Chene, Genevieve
– sequence: 27
  givenname: Jesper
  surname: Grarup
  fullname: Grarup, Jesper
– sequence: 28
  givenname: Ole
  surname: Kirk
  fullname: Kirk, Ole
– sequence: 29
  givenname: Hansjakob Furrer Anne
  surname: Johnson
  fullname: Johnson, Hansjakob Furrer Anne
– sequence: 30
  givenname: Carlo
  surname: Torti
  fullname: Torti, Carlo
– sequence: 31
  givenname: Giota
  surname: Touloumi
  fullname: Touloumi, Giota
– sequence: 32
  givenname: Laurence
  surname: Meyer
  fullname: Meyer, Laurence
– sequence: 33
  givenname: François
  surname: Dabis
  fullname: Dabis, François
– sequence: 34
  givenname: Murielle Mary
  surname: Krause
  fullname: Krause, Murielle Mary
– sequence: 35
  givenname: Jade
  surname: Ghosn
  fullname: Ghosn, Jade
– sequence: 36
  givenname: Frank
  surname: de Wolf
  fullname: de Wolf, Frank
– sequence: 37
  givenname: Maria
  surname: Prins
  fullname: Prins, Maria
– sequence: 38
  givenname: Heiner
  surname: Bucher
  fullname: Bucher, Heiner
– sequence: 39
  givenname: Diana
  surname: Gibb
  fullname: Gibb, Diana
– sequence: 40
  givenname: Osamah
  surname: Hamouda
  fullname: Hamouda, Osamah
– sequence: 41
  givenname: Barbara
  surname: Bartmeyer
  fullname: Bartmeyer, Barbara
– sequence: 42
  givenname: Julia
  surname: Del Amo
  fullname: Del Amo, Julia
– sequence: 43
  givenname: Claire
  surname: Thorne
  fullname: Thorne, Claire
– sequence: 44
  givenname: Christoph
  surname: Stephan
  fullname: Stephan, Christoph
– sequence: 45
  givenname: Santiago
  surname: Pérez-Hoyos
  fullname: Pérez-Hoyos, Santiago
– sequence: 46
  givenname: Antoni
  surname: Noguera-Julian
  fullname: Noguera-Julian, Antoni
– sequence: 47
  givenname: Andrea
  surname: Antinori
  fullname: Antinori, Andrea
– sequence: 48
  givenname: Antonella d' Arminio
  surname: Monforte
  fullname: Monforte, Antonella d' Arminio
– sequence: 49
  givenname: José
  surname: Ramos
  fullname: Ramos, José
– sequence: 50
  givenname: Manuel
  surname: Battegay
  fullname: Battegay, Manuel
– sequence: 51
  givenname: Andri
  surname: Rauch
  fullname: Rauch, Andri
– sequence: 52
  givenname: Cristina
  surname: Mussini
  fullname: Mussini, Cristina
– sequence: 53
  givenname: Pat
  surname: Tookey
  fullname: Tookey, Pat
– sequence: 54
  givenname: Jose M
  surname: Miro
  fullname: Miro, Jose M
– sequence: 55
  givenname: Stephane
  surname: de Wit
  fullname: de Wit, Stephane
– sequence: 56
  givenname: Tessa
  surname: Goetghebuer
  fullname: Goetghebuer, Tessa
– sequence: 57
  givenname: Ramon
  surname: Teira
  fullname: Teira, Ramon
– sequence: 58
  givenname: Myriam
  surname: Garrido
  fullname: Garrido, Myriam
– sequence: 59
  givenname: Ali
  surname: Judd
  fullname: Judd, Ali
– sequence: 60
  givenname: David
  surname: Haerry
  fullname: Haerry, David
– sequence: 61
  givenname: Ian
  surname: Weller
  fullname: Weller, Ian
– sequence: 62
  givenname: Céline
  surname: Fabre-Colin
  fullname: Fabre-Colin, Céline
– sequence: 63
  givenname: Christine
  surname: Schwimmer
  fullname: Schwimmer, Christine
– sequence: 64
  givenname: Monique
  surname: Termote
  fullname: Termote, Monique
Copyright COPYRIGHT 2013 Public Library of Science
2013 Mocroft et al 2013 Mocroft et al
2013 Mocroft et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, et al. (2013) Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 10(9): e1001510. doi:10.1371/journal.pmed.1001510
Copyright_xml – notice: COPYRIGHT 2013 Public Library of Science
– notice: 2013 Mocroft et al 2013 Mocroft et al
– notice: 2013 Mocroft et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, et al. (2013) Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med 10(9): e1001510. doi:10.1371/journal.pmed.1001510
CorporateAuthor Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord
CorporateAuthor_xml – name: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study in EuroCoord
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
IOV
ISN
ISR
7X8
7U1
C1K
5PM
DOA
CZK
DOI 10.1371/journal.pmed.1001510
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Opposing Viewpoints
Gale In Context: Canada
Gale In Context: Science
MEDLINE - Academic
Risk Abstracts
Environmental Sciences and Pollution Management
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
PLoS Medicine
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
Risk Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList



MEDLINE

MEDLINE - Academic




Risk Abstracts

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate Late Presentation of HIV Infection across Europe
EISSN 1549-1676
ExternalDocumentID 1442390586
oai_doaj_org_article_1eb678e02a8044a79a13f6588016acb1
PMC3796947
A347522590
24137103
10_1371_journal_pmed_1001510
Genre Research Support, Non-U.S. Gov't
Journal Article
Observational Study
GeographicLocations Europe
United States
Africa
GeographicLocations_xml – name: Europe
– name: United States
– name: Africa
GrantInformation_xml – fundername: Medical Research Council
  grantid: G0900274
GroupedDBID ---
123
29O
2WC
53G
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAUCC
AAWOE
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACPRK
ACUHS
ADBBV
ADRAZ
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AFXKF
AHMBA
AKRSQ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
B0M
BAWUL
BCNDV
BENPR
BPHCQ
BVXVI
BWKFM
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EAP
EAS
EBD
EBS
EJD
EMK
EMOBN
ESX
F5P
FPL
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
IHW
INH
INR
IOF
IOV
IPO
ISN
ISR
ITC
KQ8
M1P
M48
MK0
O5R
O5S
OK1
OVT
P2P
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RPM
SV3
TR2
TUS
UKHRP
WOW
XSB
YZZ
~8M
ADXHL
CGR
CUY
CVF
ECM
EIF
H13
IPNFZ
NPM
PJZUB
PPXIY
PV9
RIG
RZL
WOQ
PMFND
7X8
7U1
C1K
5PM
PUEGO
3V.
AAPBV
ABPTK
BCGST
CZK
ICW
M~E
ID FETCH-LOGICAL-c795t-1e2d6e4c4ebc1c2a5242d48ae5e991483f91958ba855bc32fe6fb3a0c4a8b2d93
IEDL.DBID M48
ISSN 1549-1676
1549-1277
IngestDate Sun Oct 01 00:20:28 EDT 2023
Wed Aug 27 01:26:03 EDT 2025
Thu Aug 21 13:54:03 EDT 2025
Fri Jul 11 05:34:29 EDT 2025
Mon Jul 21 11:25:24 EDT 2025
Tue Jun 17 21:56:09 EDT 2025
Thu Jun 12 23:40:33 EDT 2025
Tue Jun 10 20:33:10 EDT 2025
Fri Jun 27 03:41:45 EDT 2025
Fri Jun 27 05:04:27 EDT 2025
Fri Jun 27 03:34:43 EDT 2025
Thu May 22 21:19:38 EDT 2025
Mon Jul 21 05:54:39 EDT 2025
Tue Jul 01 01:44:28 EDT 2025
Thu Apr 24 23:06:21 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords HIV Infections
HIV Seropositivity
Sensitivity & Specificity
Europe
Humans
Risk Factors
Cooperative Behavior
Male
Treatment Outcome
CD4 Lymphocyte Count
Substance Abuse, Intravenous
Disease Progression
Incidence
Time Factors
Female
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
Creative Commons Attribution License
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c795t-1e2d6e4c4ebc1c2a5242d48ae5e991483f91958ba855bc32fe6fb3a0c4a8b2d93
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Conceived and designed the experiments: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK. Analyzed the data: AM JR. Wrote the first draft of the manuscript: AM. Contributed to the writing of the manuscript: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK. ICMJE criteria for authorship read and met: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK. Agree with manuscript results and conclusions: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK. Enrolled patients: AM JL MS Ad'A NB JC AC DC FD SDW GF HF AJ ML CL SM NO FP JR PR CS ASR ISL CT JW RZ CFC JK GC JG OK.
AM has received lecture fees, honoraria, and/or consultancies from Pfizer, BI, BMS, Merck, and Gilead. Ad'A is an advisory board member of BMS, Jannsen, Gilead, and ViiV. GF has received honoraria for lectures and advisory boards from Abbott, Bristol-Myers Squibb, Gilead, Janssen-Cilag, and Merck Sharp & Dohme. Research grant to GF from the German Federal Ministry of Education and Research (BMBF) 01KI1017. AJ is a Governor of the Wellcome Trust, a charitable research funding body; in 2011 was a specialist adviser to House of Lords Select Committee on HIV/AIDS; is a member of the UK Expert Advisory Group on AIDS; receives research grant funding from the UK Medical Research Council, Wellcome Trust, UK National Institute for Health Research, and Department of Health. CL has received these research grants: ANRS CMIT soutien (Aproco-Copilote ANRS CO08 HIV cohort, 1997–2012); IMMI (Cohort Fluco A(H1N1) pandemic influenza, 2009–2012); Ministère de la Santé PHRC (Bivir influenza trial, Oseltamivir Zanamivir, 2006–2012). CS has received funding for Advisory Board membership, speaker panels, and provision of educational materials for Gilead Sciences, Abbott Pharmaceuticals, ViiV, Merck Sharp & Dohme, Janssen-Cilag, and Bristol-Myers Squibb. CT has received honoraria to act as speaker at CME conferences on antiretroviral therapy and HIV disease management from several companies producing antiretroviral drugs, received travel grants to participate in scientific conferences, and acted as scientific consultant for the same companies. GC has had scientific responsibilities in projects receiving specific grant support from the French Agency for Research on AIDS and Viral Hepatitis (ANRS), the European Commission (Framework Program 7), UK Medical Research Council, US National Institute of Health (NIH), Fondation Plan Alzheimer, Gilead, Tibotec, Boehringer Ingelheim, GlaxoSmithKline, Roche, Pfizer, Merck, Abbott, Bristol-Myers Squibb, Janssen, ViiV Healthcare – these grants are managed through her Institution or a non-profit society. GC also serves as Academic Editor on PLOS ONE and is on the editorial board of the BMC Infectious Diseases Journal. OK has received honoraria, consultancy, lecture fees, and travel grants from Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck Sharp & Dohme, Roche, and ViiV Healthcare, and has served/is serving on Advisory Boards for Gilead Sciences, Merck Sharp & Dohme, and ViiV Healthcare. No other competing interests have been declared.
Membership of the Late Presenters Working Group and the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study is provided in the Acknowledgments.
OpenAccessLink https://doaj.org/article/1eb678e02a8044a79a13f6588016acb1
PMID 24137103
PQID 1443993794
PQPubID 23479
ParticipantIDs plos_journals_1442390586
doaj_primary_oai_doaj_org_article_1eb678e02a8044a79a13f6588016acb1
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3796947
proquest_miscellaneous_1458533032
proquest_miscellaneous_1443993794
gale_infotracmisc_A347522590
gale_infotracgeneralonefile_A347522590
gale_infotracacademiconefile_A347522590
gale_incontextgauss_ISR_A347522590
gale_incontextgauss_ISN_A347522590
gale_incontextgauss_IOV_A347522590
gale_healthsolutions_A347522590
pubmed_primary_24137103
crossref_citationtrail_10_1371_journal_pmed_1001510
crossref_primary_10_1371_journal_pmed_1001510
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2013-09-01
PublicationDateYYYYMMDD 2013-09-01
PublicationDate_xml – month: 09
  year: 2013
  text: 2013-09-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: San Francisco, USA
PublicationTitle PLoS medicine
PublicationTitleAlternate PLoS Med
PublicationYear 2013
Publisher Public Library of Science
Public Library of Science (PLoS)
Publisher_xml – name: Public Library of Science
– name: Public Library of Science (PLoS)
References ref35
ref34
TC Quinn (ref7) 2000; 342
BJ Turner (ref37) 2000; 160
N Dickson (ref26) 2012; 13
A Antinori (ref2) 2011; 12
CA Sabin (ref5) 2004; 18
M Battegay (ref4) 2007; 12
E Lanoy (ref6) 2007; 12
MA d'Arminio (ref15) 2011; 16
Y Yazdanpanah (ref12) 2010; 15 Suppl 1
L Camoni (ref16) 2013; 13
E Girardi (ref32) 2007; 46 Suppl 1
JH Samet (ref29) 1998; 158
A Zoufaly (ref14) 2012; 13
TR Chadborn (ref28) 2006; 20
B Ndiaye (ref19) 2011; 11
M Johnson (ref36) 2010; 15 Suppl 1
BM Mathers (ref25) 2010; 375
J Deblonde (ref11) 2010; 20
C Delpierre (ref30) 2008; 18
N Vives (ref17) 2012; 23
J Reekie (ref31) 2012; 7
PG de Olalla (ref22) 2011; 8
J Kjaer (ref13) 2004; 9
ref20
JA Fleishman (ref10) 2010; 48
ref21
M Helleberg (ref18) 2012; 44
J Castilla (ref23) 2002; 16
AK Sullivan (ref27) 2013; 8
ref8
E Jolley (ref33) 2012; 2
ref3
E Girardi (ref1) 2004; 36
HB Krentz (ref9) 2010; 24
E Couturier (ref24) 1998; 12
References_xml – volume: 13
  start-page: 281
  year: 2013
  ident: ref16
  article-title: Late presenters among persons with a new HIV diagnosis in Italy, 2010–2011
  publication-title: BMC Public Health
  doi: 10.1186/1471-2458-13-281
– volume: 46 Suppl 1
  start-page: S3
  year: 2007
  ident: ref32
  article-title: Late diagnosis of HIV infection: epidemiological features, consequences and strategies to encourage earlier testing
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/01.qai.0000286597.57066.2b
– ident: ref3
– volume: 11
  start-page: 11
  year: 2011
  ident: ref19
  article-title: Factors associated with presentation to care with advanced HIV disease in Brussels and Northern France: 1997–2007
  publication-title: BMC Infect Dis
  doi: 10.1186/1471-2334-11-11
– volume: 20
  start-page: 2371
  year: 2006
  ident: ref28
  article-title: The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004)
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e32801138f7
– volume: 160
  start-page: 2614
  year: 2000
  ident: ref37
  article-title: Delayed medical care after diagnosis in a US national probability sample of persons infected with human immunodeficiency virus
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.160.17.2614
– ident: ref20
– volume: 44
  start-page: 282
  year: 2012
  ident: ref18
  article-title: Late presenters, repeated testing, and missed opportunities in a Danish nationwide HIV cohort
  publication-title: Scand J Infect Dis
  doi: 10.3109/00365548.2011.626440
– volume: 7
  start-page: e41673
  year: 2012
  ident: ref31
  article-title: Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0041673
– volume: 18
  start-page: 345
  year: 2008
  ident: ref30
  article-title: Characteristics trends, mortality and morbidity in persons newly diagnosed HIV positive during the last decade: the profile of new HIV diagnosed people
  publication-title: Eur J Public Health
  doi: 10.1093/eurpub/ckm117
– volume: 16
  start-page: 1103
  year: 2011
  ident: ref15
  article-title: Late presenters in new HIV diagnoses from an Italian cohort of HIV-infected patients: prevalence and clinical outcome
  publication-title: Antivir Ther
  doi: 10.3851/IMP1883
– volume: 24
  start-page: 2750
  year: 2010
  ident: ref9
  article-title: Despite CD4 cell count rebound the higher initial costs of medical care for HIV-infected patients persist 5 years after presentation with CD4 cell counts less than 350 mul
  publication-title: AIDS
  doi: 10.1097/QAD.0b013e32833f9e1d
– volume: 15 Suppl 1
  start-page: 17
  year: 2010
  ident: ref12
  article-title: Earlier testing for HIV–how do we prevent late presentation?
  publication-title: Antivir Ther
  doi: 10.3851/IMP1526
– volume: 375
  start-page: 1014
  year: 2010
  ident: ref25
  article-title: HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60232-2
– volume: 12
  start-page: 89
  year: 2007
  ident: ref6
  article-title: Frequency, determinants and consequences of delayed access to care for HIV infection in France
  publication-title: Antivir Ther
  doi: 10.1177/135965350701200111
– volume: 13
  start-page: 182
  year: 2012
  ident: ref26
  article-title: Late presentation of HIV infection among adults in New Zealand: 2005–2010
  publication-title: HIV Med
  doi: 10.1111/j.1468-1293.2011.00959.x
– volume: 16
  start-page: 1945
  year: 2002
  ident: ref23
  article-title: Late diagnosis of HIV infection in the era of highly active antiretroviral therapy: consequences for AIDS incidence
  publication-title: AIDS
  doi: 10.1097/00002030-200209270-00012
– volume: 12
  start-page: 795
  year: 1998
  ident: ref24
  article-title: Determinants of delayed diagnosis of HIV infection in France, 1993–1995
  publication-title: AIDS
  doi: 10.1097/00002030-199807000-00016
– volume: 18
  start-page: 2145
  year: 2004
  ident: ref5
  article-title: Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy
  publication-title: AIDS
  doi: 10.1097/00002030-200411050-00006
– volume: 9
  start-page: 631
  year: 2004
  ident: ref13
  article-title: HIV cohort collaborations: proposal for harmonization of data exchange
  publication-title: Antivir Ther
  doi: 10.1177/135965350400900421
– volume: 342
  start-page: 921
  year: 2000
  ident: ref7
  article-title: Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group
  publication-title: N Engl J Med
  doi: 10.1056/NEJM200003303421303
– volume: 20
  start-page: 422
  year: 2010
  ident: ref11
  article-title: Barriers to HIV testing in Europe: a systematic review
  publication-title: Eur J Public Health
  doi: 10.1093/eurpub/ckp231
– ident: ref21
– volume: 48
  start-page: 1071
  year: 2010
  ident: ref10
  article-title: The economic burden of late entry into medical care for patients with HIV infection
  publication-title: Med Care
  doi: 10.1097/MLR.0b013e3181f81c4a
– volume: 15 Suppl 1
  start-page: 3
  year: 2010
  ident: ref36
  article-title: Definition and epidemiology of late presentation in Europe
  publication-title: Antivir Ther
  doi: 10.3851/IMP1522
– volume: 13
  start-page: 172
  year: 2012
  ident: ref14
  article-title: Late presentation for HIV diagnosis and care in Germany
  publication-title: HIV Med
  doi: 10.1111/j.1468-1293.2011.00958.x
– volume: 23
  start-page: 475
  year: 2012
  ident: ref17
  article-title: Factors associated with late presentation of HIV infection in Catalonia, Spain
  publication-title: Int J STD AIDS
  doi: 10.1258/ijsa.2011.011280
– volume: 8
  start-page: 22
  year: 2011
  ident: ref22
  article-title: Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001–2009
  publication-title: AIDS Res Ther
  doi: 10.1186/1742-6405-8-22
– ident: ref8
– volume: 12
  start-page: 61
  year: 2011
  ident: ref2
  article-title: Late presentation of HIV infection: a consensus definition
  publication-title: HIV Med
  doi: 10.1111/j.1468-1293.2010.00857.x
– volume: 36
  start-page: 951
  year: 2004
  ident: ref1
  article-title: Delayed presentation and late testing for HIV: demographic and behavioral risk factors in a multicenter study in Italy
  publication-title: J Acquir Immune Defic Syndr
  doi: 10.1097/00126334-200408010-00009
– volume: 2
  year: 2012
  ident: ref33
  article-title: HIV among people who inject drugs in Central and Eastern Europe and Central Asia: a systematic review with implications for policy
  publication-title: BMJ Open
  doi: 10.1136/bmjopen-2012-001465
– ident: ref34
  doi: 10.2807/ese.16.48.20030-en
– volume: 12
  start-page: 841
  year: 2007
  ident: ref4
  article-title: Late presentation of HIV-infected individuals
  publication-title: Antivir Ther
  doi: 10.1177/135965350701200612
– ident: ref35
– volume: 158
  start-page: 734
  year: 1998
  ident: ref29
  article-title: Trillion virion delay: time from testing positive for HIV to presentation for primary care
  publication-title: Arch Intern Med
  doi: 10.1001/archinte.158.7.734
– volume: 8
  start-page: e52845
  year: 2013
  ident: ref27
  article-title: Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV Indicator Diseases across Europe Study)
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0052845
SSID ssj0029090
Score 2.5495183
Snippet Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the...
Background: Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to...
Please see later in the article for the Editors' Summary.
Amanda Mocroft and colleagues investigate risk factors and health outcomes associated with diagnosis at a late stage of infection in individuals across Europe....
BackgroundFew studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to...
  Background Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to...
SourceID plos
doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage e1001510
SubjectTerms Acquired immune deficiency syndrome
AIDS
Care and treatment
CD4 Lymphocyte Count
Collaboration
Cooperative Behavior
Disease Progression
Europe - epidemiology
Female
HIV
HIV infection
HIV Infections - diagnosis
HIV Infections - epidemiology
HIV Infections - immunology
HIV patients
HIV Seropositivity - epidemiology
Host-parasite relationships
Human immunodeficiency virus
Humans
Illnesses
Immune system
Incidence
Infections
Male
Medical tests
Medicine
Mortality
Patient outcomes
Risk Factors
Sensitivity and Specificity
Studies
Substance Abuse, Intravenous - epidemiology
Time Factors
Treatment Outcome
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bb9MwFLZQHxAviPsyNjAIcXkIS2LnxtuoOnVIW6XCpr1FtmOPii6plhaJP8bv4xzHzRo0sT3w0ofki9v6HB9_jo-_Q8gb8IEkzYXxVShSH3cCfZiEpc9UDATfBGFpk2iOjpPxCf9yFp9tlPrCnLBWHrjtuL1QS4inOohEFnAuoN2QGZg2IbImQkm78IE5b72YckutPLBvV1B_zA-jNHWH5lga7jkbfVzAbGMViGI8PbsxKVnt_i5CDxbzurmOfv6dRbkxLR08IPcdn6T77f94SO7o6hG5e-R2zB-T39NZ84O6qjpUVCWtV0vwMt1QoKt0DlSTLq6OIFX26vjw1G-zuX7CXcvJGzqraPvq_hMF_Gq-hBYu6wsKDJION72J1oZOZPe2F34dtEdHV6Vo0S_oOuXPNUoxofEXfT-cjEfT0Ycn5ORg9G049l2tBl-lebz0Qx2VieaKa6lCFYkYpv6SZ0LHGhgoz5jJUdZGiiyOpWKR0YmRTASKi0xGZc6ekkFVV3qL0CzAslgo7C8zzg2HjxyIJ0QXY8pIxh5ha2MVygmZYz2NeWF351JY0LR9X6CJC2dij_jdU4tWyOMG_Gf0gw6LMtz2Ajhn4ZyzuMk5PfISvahoz7R2waTYZzwF4hvn8DWvLQKlOCrM9TkXq6YpDientwB9Pb4NaNoDvXMgU0OfKeEOYUDPow5YD_m2hzxvVdCvA-70gBCeVO_2Fo6gdR83sNZEzckgzhKPvFqPqgKfwnS_Stcri7HEOef_wsBKlwEDizzyrB2JnbFwsxioM_NI2hujPWv271Sz71ZcHb40yXm6_T_M_5zci2z1FExJ3CGD5eVK7wKHXcoXNlz9AVbnmC8
  priority: 102
  providerName: Directory of Open Access Journals
Title Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
URI https://www.ncbi.nlm.nih.gov/pubmed/24137103
https://www.proquest.com/docview/1443993794
https://www.proquest.com/docview/1458533032
https://pubmed.ncbi.nlm.nih.gov/PMC3796947
https://doaj.org/article/1eb678e02a8044a79a13f6588016acb1
http://dx.doi.org/10.1371/journal.pmed.1001510
Volume 10
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bb9MwFLZGJyFeJu4LjGIQ4vKQKRcnTpAQ2qpOHagtFDr1LbIdp1SUpDQtYn-M38ex42YLKrCXPCRfnMg-x_5sH38HoWdgAyGNWWYLl1Fb7QTaMAhz2xcBEPzMcVMdRNMfhL0xeTcJJjtok7PVVGC5dWqn8kmNl_PDn9_P34LDv9FZG6i7eelwAeOH1hQK1JmrXRibqHLVPqn3FbzY0asuSpfMdkMamsN0fyulMVhpTf-6524t5kW5jZb-GV15abg6uYn2DM_ER5Vh3EI7Mr-NrvfNTvod9Gs0K79ik20HszzFxXoF1idLDDQWz4GC4sXF0aRc3-2dntlVlNcPeKq5eolnOa6W9F9jwK_nKyhhWXzDwCxx57KV4SLDQ16vAsPfQXm4e5GiVtkL3oQCmkKxCnQ8xy87w1531H11F41Pup87PdvkcLAFjYOV7UovDSURRHLhCo8FQAlSEjEZSGCmJPKzWMndcBYFARe-l8kw4z5zBGER99LYv4daeZHLfYQjR6XLUoL_PCIkI3CJgZBCr5NlqccDC_mbxkqEEThXeTbmid61ozDRqeo-UU2cmCa2kF2_tagEPv6DP1Z2UGOVPLe-USynifH2xJUcSIB0PBY5hDBwBtfPgOsBHQiZ4K6FHisrSqqzrnUnkxz5hAIhDmL4zFONUBIduYoBmrJ1WSanw7MrgD4NrgIaNUAvDCgroM4EM4czoOaVPlgD-byBnFbq6NuABw0gdFui8XhfedCmjkuYgyotSieIQgs92XhVot5SYYC5LNYaowl1TP6FgRmwD8zMs9D9yhPrxlKbyECpfQvRho82WrP5JJ990aLr8NEwJvTBFf7tIbrh6aQpKhLxALVWy7V8BNR1xdvoGp3QNto97g4-jNp6AQiu7z9Gbd1P_QaIaJyh
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk+factors+and+outcomes+for+late+presentation+for+HIV-positive+persons+in+Europe%3A+results+from+the+Collaboration+of+Observational+HIV+Epidemiological+Research+Europe+Study+%28COHERE%29&rft.jtitle=PLoS+medicine&rft.au=Mocroft%2C+Amanda&rft.au=Lundgren%2C+Jens+D&rft.au=Sabin%2C+Miriam+Lewis&rft.au=Monforte%2C+Antonella+d%27Arminio&rft.date=2013-09-01&rft.issn=1549-1676&rft.eissn=1549-1676&rft.volume=10&rft.issue=9&rft.spage=e1001510&rft_id=info:doi/10.1371%2Fjournal.pmed.1001510&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1549-1676&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1549-1676&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1549-1676&client=summon